Idiotype vaccination as consolidation therapy: Time for integration into standard of care for follicular lymphoma?

Journal of Clinical Oncology

Volumn 29, Issue 36, 2011, Pages 4545-4546

  Schuster, Stephen J ^a   Neelapu, Sattva S ^b   Santos, Carlos F ^c   Popa McKiver, Mihaela A ^c   McCord, Amy M ^c   Kwak, Larry W ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Biovest International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE; RITUXIMAB; CANCER VACCINE;

CANCER IMMUNIZATION; CANCER REGRESSION; CANCER RELAPSE; DRUG FATALITY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; NOTE; PATIENT SELECTION;

CANCER VACCINES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; PATIENT SELECTION;

EID: 84555202735     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.6094     Document Type: Letter

References (5)

1. Ansell SM, Suman VJ: Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine. J Clin Oncol 29:2748-2749, 2011
2. Schuster SJ, Neelapu SS, Gause BL, et al.: Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29:2787-2794, 2011
3. National Comprehensive Cancer Network (NCCN): NCCN clinical practice guidelines in oncology (NCCN Guidelines): Non-Hodgin's lymphomas. Version 2.2011. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
4. Salles G, Seymour JF, Offner F, et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51, 2011
5. Rummel MJ, Niederle N, Maschmeyer G, et al.: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final Results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009 (abstr 405)